rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Waar beleggen jullie nog meer in

2.899 Posts
Pagina: «« 1 ... 44 45 46 47 48 ... 145 »» | Laatste | Omlaag ↓
  2. Hansvdz 24 juni 2020 08:18

    • Hansvdz

      Lid sinds: 31 jan 2019

      Laatste bezoek: 21 okt 2024

    • Aanbevelingen

      Ontvangen: 144

      Gegeven: 0

    •    Aantal posts: 1.709

    ATNM heeft gisteren ook een mooi ritje gemaakt, heb er 9000 aan 0,38 en heeft even de 0,46 aangetikt. Heb wel nog niet verkocht, ik verwacht nog een grotere stijging.
  8. Hansvdz 24 juni 2020 13:30

    • Hansvdz

      Lid sinds: 31 jan 2019

      Laatste bezoek: 21 okt 2024

    • Aanbevelingen

      Ontvangen: 144

      Gegeven: 0

    •    Aantal posts: 1.709

    Wat ik persoonlijk nog een aandeel beschouw met koopadvies is Kosmos Energy (KOS). Stond 8 juni nog 3,43 en is nu de laatste week terug naar onder aan het gaan. Ik heb hem aan 1,8. Voor de corona stond deze +6.
  13. [verwijderd] 24 juni 2020 14:14

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    En goed nieuws BIOC:

    Biocept Enters Into Agreement with Reference-based Pricing Network Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims
    PR Newswire PR Newswire•June 24, 2020
    SAN DIEGO, June 24, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces it has entered into a managed care provider agreement with Medical Cost Containment Professionals, LLC (MCCP) to process out-of-network claims for Biocept's Target Selector™ liquid biopsy testing. MCCP is a reference-based pricing insurance network that includes more than 150,000 providers nationwide.

    Biocept Logo (PRNewsFoto/Biocept, Inc.)
    Biocept Logo (PRNewsFoto/Biocept, Inc.)
    More
    "MCCP has a reputation for paying out-of-network claims correctly, in full and on time; and we are delighted to be working with them," said Dede Goehler, Biocept's Senior Director of Managed Care Strategies. "Under this new relationship, out-of-network claims for our Target Selector™ testing will be adjudicated by MCCP at pre-negotiated pricing in a timely manner, helping to accelerate collections while reducing the length of time receivables remain outstanding."

    "This agreement effectively expands our managed care network of covered lives at a time when the healthcare community increasingly recognizes the importance of our liquid biopsy tests in helping physicians to determine the optimal treatment for their patients with cancer," said Michael Nall, Biocept's President and CEO. "MCCP's network includes 47 million covered lives, with some members covered by multiple plans. We are working to enter into additional similar partnerships that help adjudicate out-of-network claims, as well as with managed care plans for in-network coverage for their members."

    About MCCP
    Medical Cost Containment Professionals, LLC was founded by Principal and CEO Daniel Ayala to help lower the cost of healthcare throughout America. MCCP has been successful in driving down the cost of business for its clients. MCCP's unique business model allows for negotiation of 80% of the claims it receives regardless of the amount. More information is available at www.mccpppo.com.

    About Biocept
    Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. Additionally, Biocept is offering nationwide COVID-19 polymerase chain reaction (PCR) testing to support public health efforts during this unprecedented pandemic. For more information, please visit www.biocept.com.

    Forward-Looking Statements Disclaimer Statement
    This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding the adjudication of testing by MCCP at pre-negotiated pricing in a timely manner and the benefits thereof, the ability of MCCP to negotiate 80% of the claims it receives regardless of the amount, the ability of our platform to identify cancer mutations and alterations, and the ability of our technologies to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. You are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

    Continue reading
  15. [verwijderd] 24 juni 2020 15:25

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    KC 1965 schreef op 23 juni 2020 19:06:

    Zojuist SINT gekocht aan 1,36, hopelijk herstelt dat snel:

    SINTX Technologies Inc (SINT)

    NASDAQ

    Melding aanmaken
    Voeg toe aan Portfolio
    1,370 -0,650 -32,18%
    19:04:09 - Real-time Cboe. Valuta in USD ( Algemene voorwaarden )
    Type: Aandeel
    Markt: Verenigde Staten
    ISIN: US8293923079
    CUSIP:

    Dit aandeel heeft ook een PR geplaatst:

    SINTX TECHNOLOGIES ANNOUNCES PUBLICATION OF STUDY TO REDUCE THE SPREAD AND TRANSFER OF CORONAVIRUS
    GlobeNewswire GlobeNewswire•June 24, 2020
    Silicon nitride demonstrates anti-viral properties against SARS-CoV-2 and kills virus within minutes of exposure.

    SALT LAKE CITY, UT, June 24, 2020 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (SINT) (“SINTX” or the “Company”), an original equipment manufacturer (OEM) ceramics company focused on silicon nitride and its applications, today announced positive testing results demonstrating the anti-viral properties of its silicon nitride which may be useful in the reduction of the spread of COVID-19. The study results demonstrated that SINTX’s unique grade of silicon nitride inactivates the SARS-CoV-2 virus within a minute after exposure, and has the potential to decrease the risk of viral disease spread on surfaces.

    Studies have shown that coronavirus spreads between humans when an infected person coughs or sneezes. Also, the virus can remain active on a variety of commonly touched surfaces for hours to days. SINTX believes that by incorporating its unique composition of silicon nitride into products such as face masks, and personal protective equipment, it is possible to manufacture surfaces that inactivate viral particles, thereby limiting the spread of the disease. SINTX envisions incorporating its silicon nitride into high-contact surfaces such as medical equipment, screens, countertops, and doorknobs in locations where viral persistence is a concern, such as homes, casinos, and cruise ships.

    “The study builds upon years of research toward understanding the basic biochemistry of silicon nitride,” said Dr. Sonny Bal, President, and CEO of SINTX. “The antiviral attributes of silicon nitride are consistent with the known antibacterial behavior of silicon nitride. The results with coronavirus inactivation are likewise consistent with an earlier study that showed similar inactivation of other viruses, including Influenza A and Enterovirus, both of which cause human disease.”

    “The study and testing results show promise toward developing a new category of face masks for healthcare professionals and general consumers,” said Bruce Lorange, Founder, and CEO, O2TODAY. “Face masks used by healthcare workers today can capture virus particles, but the virus can remain viable in the mask, even as long 7 days after use. Inclusion of silicon nitride technology into the mask may enhance personal safety while reducing the risk of disease spread.”

    “This antiviral discovery opens many new opportunities for SINTX. In composites, coatings, and mixtures, silicon nitride has maintained its antibacterial and osteogenic properties, even at small fractions. We believe that incorporating our material into a variety of commonly-touched surfaces will discourage viral spread, and contribute to global health by reducing the risk of disease,” Dr. Bal added.

    The present study was done independently, with SINTX supplying its silicon nitride for the testing. The complete data and study can be downloaded at bioRxiv. Additional tests are underway at several U.S. research centers to further understand the isolation and optimization of the antiviral properties of silicon nitride; those results will be shared as they become available.

    About SINTX Technologies, Inc.

    SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company manufactures silicon nitride material and components in its FDA registered and ISO 13485 certified facility. For more information on SINTX Technologies or its silicon nitride material platform, please visit www.sintx.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (PSLRA) that are subject to several risks and uncertainties. Risks and uncertainties that may cause such differences to include, among other things, that SINTX has not developed any PPE products which incorporate the use of silicon nitride, incorporation of silicon nitride into PPE may not be safe or effective; the uncertainties inherent in research and development, including the cost and time required to advance our products to regulatory submission; market acceptance of our products once cleared and commercialized; our ability to raise additional funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations, and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 26, 2020, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

    Continue reading

    Laat maar knallen vandaag, gisteren ingestapt aan 1,36

    1,420 -0,590 -29,35%
    23/06 - Gesloten. Valuta in USD ( Algemene voorwaarden )
    Voorbeurs 1,620 +0,200 +14,08% 15:23:22 - Real-time Data
    Type: Aandeel
    Markt: Verenigde Staten
    ISIN: US8293923079
    CUSIP: 829392307
    Volume: 19.896.889 Bied/laat: 1,600 / 1,630 Dagbereik: 1,310 - 1,580
    SINTX Technologies 1,420 -0,590 -29,35%
    Algemeen Grafiek Financiën Technisch Forum
  16. [verwijderd] 24 juni 2020 15:34

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    SINTX Technologies Inc (SINT)

    NASDAQ

    Melding aanmaken
    Voeg toe aan Portfolio
    1,720 +0,320 +22,86%
    15:33:45 - Real-time Cboe. Valuta in USD ( Algemene voorwaarden )
    Type: Aandeel
    Markt: Verenigde Staten
  18. CedricPalmans 24 juni 2020 15:39

    • CedricPalmans

      Lid sinds: 15 dec 2016

      Laatste bezoek: 07 mei 2024

    • Aanbevelingen

      Ontvangen: 10

      Gegeven: 2

    •    Aantal posts: 59

    quote:

    KC 1965 schreef op 24 juni 2020 14:10:

    En ik denk met goed nieuws dat dit makkelijk 6-7,- doet.
    met alle respect, maar ik vind dit slaat toch werkelijk nergens op? Waarom zou dat op basis van die info manifest gaan stijgen? Naar 6 betekent 20% omhoog. Omdat ze beginnen testen zijn, wat ze vorige week al hadden aangekondigd?
    Van mij mag het zeker, want ik zit er in, en aan een hogere prijs dan de huidige koers.
    Koersstijgingen verwacht ik pas als er een akkoord is met andere luchthavens, of als er resultaten zijn van hoe het operationeel draait.
  19. CedricPalmans 24 juni 2020 15:40

    • CedricPalmans

      Lid sinds: 15 dec 2016

      Laatste bezoek: 07 mei 2024

    • Aanbevelingen

      Ontvangen: 10

      Gegeven: 2

    •    Aantal posts: 59

    quote:

    Gaizka1985 schreef op 24 juni 2020 09:37:

    [...]

    En daar is het nieuws! Ben benieuwd waar de koers naartoe gaat vandaag!
    Ze hadden vorige week al aangegeven dat ze eind deze week gingen beginnnen testen. Weinig wereldschokkends. 't is wachten op andere akkoorden, of goeie resultaten qua operationele werking.
  21. CedricPalmans 24 juni 2020 16:02

    • CedricPalmans

      Lid sinds: 15 dec 2016

      Laatste bezoek: 07 mei 2024

    • Aanbevelingen

      Ontvangen: 10

      Gegeven: 2

    •    Aantal posts: 59

    Akkoord daarmee, maar zeggen dat op basis van dat nieuws, dat al bekend was, de koers naar 6 of 7 gaat, dat houdt totaal geen steek. Want het was al geweten.
2.899 Posts
Pagina: «« 1 ... 44 45 46 47 48 ... 145 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.076
AB InBev 2 5.522
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.756
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.755
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 191
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.754
Aedifica 3 919
Aegon 3.258 322.906
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.895
Agfa-Gevaert 14 2.051
Ahold 3.538 74.342
Air France - KLM 1.025 35.089
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.943
Allfunds Group 4 1.503
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.823
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.411
AMG 971 133.781
AMS 3 73
Amsterdam Commodities 305 6.697
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.017
Apollo Alternative Assets 1 17
Apple 5 383
Arcadis 252 8.786
Arcelor Mittal 2.034 320.776
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.326
Aroundtown SA 1 219
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.338
ASML 1.766 108.282
ASR Nederland 21 4.502
ATAI Life Sciences 1 7
Atenor Group 1 515
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.688
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.404